Does Wegovy Cause Muscle Wasting — and What Can You Do About It?

Does Wegovy specifically cause more muscle loss than other weight-loss methods?

Not more, but not less, either. Any meaningful weight-loss intervention involves losing some lean mass alongside fat. The body does not shed fat in isolation. What the research shows for semaglutide is broadly in line with what is seen after other approaches: roughly a quarter to just under half of total body-weight lost during treatment comes from lean tissue rather than fat. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, a meaningful result, but one that involved the full mix of tissue types you would expect.

The concern specific to GLP-1 medicines is speed and appetite suppression. When eating drops sharply, protein intake often drops with it, and protein is what muscle relies on for repair and maintenance. The medicine itself does not appear to directly damage muscle tissue, but the caloric restriction it drives can deprive muscles of what they need. That distinction matters for what you can actually do about it.

If you are weighing up semaglutide more broadly, the Wegovy treatment overview on this site covers the licensed indications and how the medicine works in more detail.

What does the research say about lean mass loss in practice?

Several analyses of the STEP trial programme looked at body composition specifically, not just weight on the scales. They consistently found that the majority of weight lost (typically around 60–75%) was fat mass. The remaining fraction was lean mass, which includes muscle but also water, glycogen stored in muscle, and connective tissue. Losing some of that is biologically normal when body weight drops substantially.

Where the picture becomes more nuanced is in people who are losing weight quickly, eating very little protein, or doing no resistance activity. In those circumstances the lean-mass fraction of total weight loss can edge higher. Conversely, people who prioritised protein and kept up strength training during the STEP trials tended to preserve more lean mass. The NHS semaglutide medicines page notes the importance of following dietary advice alongside treatment, the two are not separable.

Concerns about related symptoms are worth separating out. Muscle aches and cramps during treatment tend to have different explanations (often dehydration from GI side effects or electrolyte shifts from eating less) and are covered in more detail on whether Wegovy can cause muscle aches and muscle cramps during semaglutide treatment.

What actually helps preserve muscle while taking Wegovy?

Two things matter more than anything else: protein and resistance exercise. Protein targets during active weight loss are generally higher than most people assume. Mainstream dietary guidance is set for weight maintenance; when losing weight, particularly with the significant appetite suppression semaglutide produces, most people need to be deliberate about hitting a protein target at every meal rather than relying on natural appetite cues. Your prescriber or a registered dietitian can help you work out a realistic figure for your body weight and activity level.

Resistance training (anything that challenges your muscles against load, from gym weights to bodyweight exercises) is the other half of the equation. It signals to the body that muscle is needed, even in a calorie deficit. Cardio alone does not send the same signal.

Fatigue during treatment can make it harder to exercise consistently. If you are experiencing significant tiredness, our page on Wegovy and lethargy goes into the likely causes and practical ways to manage energy levels. General questions about what life on treatment is like are answered in the patient FAQs.

One practical note: because Wegovy is a prescription medicine, the dose schedule is set and reviewed by your prescriber. Titration timing and any changes to your plan (including how to adjust eating and exercise at each stage) belong in that clinical relationship, not in self-managed decisions based on general reading. If you want to explore how private Wegovy treatment is priced in the UK before starting, that page gives an honest breakdown of what affects cost.

When should muscle-related concerns be taken seriously?

Most people on Wegovy do not experience dramatic muscle weakness or wasting. The lean-mass change described above is gradual and, for the majority of patients, manageable with reasonable lifestyle measures. That said, a few situations warrant prompt contact with your prescriber rather than a wait-and-see approach.

If you notice significant, unexpected weakness (not just tiredness after a workout but a meaningful change in what you can physically do) tell your prescriber. Severe or persistent muscle pain that does not fit the pattern of normal exercise soreness is also worth investigating. Occasionally, marked protein deficiency, which can follow very restricted eating on treatment, contributes to more pronounced lean-mass loss than would otherwise occur.

The evidence on semaglutide and muscle loss looks at the broader research across the semaglutide programme, including diabetic populations, if you want more background. For symptoms that feel more acute or unusual, the muscle pain during Wegovy treatment page and the Wegovy patient information leaflet guide cover what the official guidance says about reporting symptoms. You can also reach our clinical team directly via the contact page.

If you are thinking about starting treatment and want to talk through what to expect (including how to approach nutrition and activity from day one) a free consultation with our prescribers is the most useful first step. Start your free consultation and a GPhC-registered prescriber will review your answers the same day.